Your browser doesn't support javascript.
Beneficial non-anticoagulant mechanisms underlying heparin treatment of COVID-19 patients.
Buijsers, Baranca; Yanginlar, Cansu; Maciej-Hulme, Marissa L; de Mast, Quirijn; van der Vlag, Johan.
  • Buijsers B; Department of Nephrology, Radboud Institute for Molecular Life Sciences, Radboud university medical center, Nijmegen, The Netherlands.
  • Yanginlar C; Department of Nephrology, Radboud Institute for Molecular Life Sciences, Radboud university medical center, Nijmegen, The Netherlands.
  • Maciej-Hulme ML; Department of Nephrology, Radboud Institute for Molecular Life Sciences, Radboud university medical center, Nijmegen, The Netherlands.
  • de Mast Q; Department of Internal Medicine, Radboud university medical center, Nijmegen, The Netherlands.
  • van der Vlag J; Department of Nephrology, Radboud Institute for Molecular Life Sciences, Radboud university medical center, Nijmegen, The Netherlands.
EBioMedicine ; 59: 102969, 2020 Sep.
Article in English | MEDLINE | ID: covidwho-728523
ABSTRACT
Coronavirus disease-2019 (COVID-19) is associated with severe inflammation in mainly the lung, and kidney. Reports suggest a beneficial effect of the use of heparin/low molecular weight heparin (LMWH) on mortality in COVID-19. In part, this beneficial effect could be explained by the anticoagulant properties of heparin/LMWH. Here, we summarise potential beneficial, non-anticoagulant mechanisms underlying treatment of COVID-19 patients with heparin/LMWH, which include (i) Inhibition of heparanase activity, responsible for endothelial leakage; (ii) Neutralisation of chemokines, and cytokines; (iii) Interference with leukocyte trafficking; (iv) Reducing viral cellular entry, and (v) Neutralisation of extracellular cytotoxic histones. Considering the multiple inflammatory and pathogenic mechanisms targeted by heparin/LMWH, it is warranted to conduct clinical studies that evaluate therapeutic doses of heparin/LMWH in COVID-19 patients. In addition, identification of specific heparin-derived sequences that are functional in targeting non-anticoagulant mechanisms may have even higher therapeutic potential for COVID-19 patients, and patients suffering from other inflammatory diseases.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Heparin / Coronavirus Infections / Anti-Inflammatory Agents Type of study: Experimental Studies / Prognostic study Limits: Humans Language: English Journal: EBioMedicine Year: 2020 Document Type: Article Affiliation country: J.ebiom.2020.102969

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Heparin / Coronavirus Infections / Anti-Inflammatory Agents Type of study: Experimental Studies / Prognostic study Limits: Humans Language: English Journal: EBioMedicine Year: 2020 Document Type: Article Affiliation country: J.ebiom.2020.102969